HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vekeman, F. Articles by Duh, M. S. Search for Related Content PubMed PubMed Citation Articles by Vekeman, F. Articles by Duh, M. S.

FRANCIS VEKEMAN, M.A., is Economist, Analysis Group, Inc., Montreal, Quebec, Canada. R. SCOTT MCKENZIE, M.D., is Regional Director, Ortho Biotech Clinical Affairs, LLC (OBCA), Dallas, TX. PATRICK LEFEBVRE, M.A., is Senior Economist, Analysis Group, Inc., Montreal. SUE H. WATSON, PHARM.D., is Field Director, OBCA, Richmond, TX. SAMIR H. MODY, PHARM.D., M.B.A., is Regional Associate Director, OBCA, Chapel Hill, NC. CATHERINE TAK PIECH, M.B.A ., is Vice President, OBCA, Bridgewater, NJ. MEI SHENG DUH, M.P.H., SC.D., is Vice President, Analysis Group, Inc., Boston, MA.

Address correspondence to Dr. Duh at Analysis Group, Inc., Boston, MA 02199 (mduh{at}analysisgroup.com).

Purpose. The inpatient dosing patterns and treatment costs in cancer and predialysis chronic kidney disease (CKD) patients treated with erythropoietic agents from a hospital pharmacy perspective were studied. Methods. An analysis of electronic inpatient records from the Premier Perspective comparative hospital database was conducted. Study participants were identified through hospitalizations recorded between July 2002 and March 2005 from over 500 hospitals nationwide. Adult patients with an admitting diagnosis of cancer or predialysis CKD and treated with epoetin alfa or darbepoetin alfa during hospitalization were included. Patients who had received renal dialysis or both agents during a hospitalization were excluded. Wholesale acquisition costs from September 2006 were used to calculate drug costs. Results. A total of 25,645 hospitalized patients with cancer (22,873 received epoetin alfa; 2,772 received darbepoetin alfa) and 66,822 hospitalized patients with CKD (60,079 received epoetin alfa; 6,743 received darbepoetin alfa) were identified. The mean cumulative dose per hospitalization resulted in dose ratios of 245:1 and 242:1 (units epoetin alfa:micrograms darbepoetin alfa) for cancer and CKD patients, respectively. On the basis of the cumulative dose per hospitalization, drug costs for darbepoetin alfa-treated patients were approximately 50% higher than drug costs for epoetin alfa-treated patients for both oncology and CKD patients. Conclusion. Epoetin alfa was associated with less cost compared with darbepoetin alfa for treating inpatients with cancer or CKD. Further research including the patients’ clinical outcomes is necessary to determine the true pharmacoeconomic differences between the two agents. Index terms: Costs; Darbepoetin alfa; Dosage; Drug comparisons; Epoetin alfa; Hematopoietic agents; Kidney diseases; Neoplasms